Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 18;14:17562864211006503. doi: 10.1177/17562864211006503

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2021

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — Radiological characteristics of two patients presented with Marburg-like tumefactive lesions. Bilateral Marburg-like tumefactive lesions of a patient at disease onset [(a)–(c)], after chronic treatment with mitoxantrone, cyclophosphamide, and glatiramer acetate showing significant resolution of the lesions [(d) and (e)]. This patient, 10 years after disease onset has an EDSS score of 1. A second patient with Marburg-like demyelination in the right centrum semiovale at onset [(f)] with Gd+ [(g)] and after three monthly cycles of cyclophosphamide. A significant resolution of the tumefactive lesion with no Gd+ was observed after three monthly cycles of cyclophosphamide [(h) and (i)] with EDSS score 1.5.

T2-weighted images: (a), (b), (d) to (f). FLAIR images: (c), (h). T1-weighted contrast-enhanced images: (g), (i).

EDSS, Expanded Disability Status Scale; FLAIR, fluid-attenuated inversion recovery; Gd+, gadolinium enhancement.